Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05800587 · ClinicalTrials.gov registry record · Phase 2
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
A Phase 2 study of Non-Small Cell Lung Cancer and Lung Cancer, sponsored by Fox Chase Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 280
- Enrollment target
- 1
- Study location
NCT05800587 is a Phase 2 study of Non-Small Cell Lung Cancer and Lung Cancer that is actively recruiting participants, run by Fox Chase Cancer Center. The registered enrollment target is 280 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (57% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05800587, a Phase 2 study of Non-Small Cell Lung Cancer and Lung Cancer, is actively recruiting participants, sponsored by Fox Chase Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 280 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label, non-randomized, single-center, phase II study to evaluate the efficacy, toxicity and, tolerability of pre-specified dose attenuated chemotherapy regimens in lung cancer patients with comorbidities.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Docetaxel
- DRUG Pemetrexed
- DRUG Paclitaxel
- DRUG Nab paclitaxel
Study Locations (1)
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280 participants |
| Start Date | 2023-02-22 |
| Est. Completion | 2029-08-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05800587
The ClinicalTrials.gov registry entry for NCT05800587 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 280 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (57% lower). The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT05800587 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05800587 about?
NCT05800587 is a clinical study titled "Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer". This is an open-label, non-randomized, single-center, phase II study to evaluate the efficacy, toxicity and, tolerability of pre-specified dose attenuated chemotherapy regimens in lung cancer patients with comorbidities.
What is the current status of trial NCT05800587?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 280 participants. The study started on 2023-02-22. Estimated completion is 2029-08-01.
What conditions does trial NCT05800587 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Lung Cancer, Small-cell Lung Cancer.
What interventions are being tested in trial NCT05800587?
The interventions under investigation include: Carboplatin (DRUG), Docetaxel (DRUG), Pemetrexed (DRUG), Paclitaxel (DRUG), Nab paclitaxel (DRUG).
Who is sponsoring clinical trial NCT05800587?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05800587 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.